Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia

Susanne K. Pedersen; Erin L. Symonds; Rohan T. Baker; David H. Murray; Aidan McEvoy; Sascha C. Van Doorn; Marco W. Mundt; Stephen R. Cole; Geetha Gopalsamy; Dileep Mangira; Lawrence C. LaPointe; Evelien Dekker; Graeme P. Young

doi:10.1186/s12885-015-1674-2

Table 2 Methylation marker performance by clinical findings, including selected sub-categories

From: Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia

Most advanced findings	No. (%)	Positivity Counts (%); 95 % CI
Most advanced findings	No. (%)	BCAT1	IKZF1	Either marker	OR (95 % CI)¹	X ²
ALL CASES	2101	181 (9); 8-10	89 (4); 3-5	204 (10); 8-11
Cancer	129 (6)	74 (57); 48 - 66	62 (48); 39 - 57	85 (66); 57 - 74	34 (20 - 59)**	241**
Stage I	29 (22)	7 (24); 10 - 44	8 (28); 13 - 47	11 (38); 21 - 58	11 (5 - 26)**	43**
Stage II	42 (33)	26 (62); 46 - 76	17 (40); 26 - 57	29 (69); 53 - 82	40 (18 - 86)**	16**
Stage III	40 (31)	27 (68); 51 - 81	22 (55); 38 - 71	29 (73); 56 - 85	47 (21 - 105)**	172**
Stage IV	16 (12)	13 (81); 54 - 96	15 (94);70 - 100	15 (94);70 - 100	266 (34-2101)**	158**
Unstaged	2 (2)	1 (50); 1 - 99	0 (0); 0 - 80	1 (50); 1 - 99	18 (1 - 293)**	8*
Early Stage (I + II)	71 (55)	33 (46); 35 - 59	25 (35); 24 - 47	40 (56); 44 - 68	23 (12 - 43)**	148**
Late Stage (III + IV)	56 (43)	40 (71); 58 - 83	37 (66); 52 - 78	44 (79); 66 - 88	65 (30 - 139)**	230**
Adv. adenoma²	338(16)	16 (5); 3 - 8	7 (2); 1 - 4	20 (6); 4 - 9	1.1 (0.6 - 2)	0.1
HGD	32 (9)	2 (6); 1 - 21	1 (3); 0.1 - 16	2 (6); 0.1 - 21	1.2 (0.3 - 5)	0.1
TVA³	144(43)	7 (5); 2 - 10	0 (0); 0 - 20	7 (5); 2 - 10	0.9 (0.4 - 2)	0.1
≥10mm⁴	107(32)	3 (3); 1 - 8	4 (4); 1 - 9	5 (5); 2 - 11	0.9 (0.3 - 2)	0.1
≥3 TAs (<10mm)	34 (10)	4 (12); 3 - 27	0 (0); 0 - 10	4 (12); 3 - 27	2.4 (1 - 7)	2.4
Serrated Adenoma	19 (6)	0 (0); 0 - 20	2 (11); 2 - 52	2 (11); 2 - 52	2 (0.5 - 10)	0.9
Non adv. adenoma	346(16)	23 (7); 4 - 10	2 (1); 0.1 - 2	23 (7); 4 - 10	1.3 (0.7 - 2)	0.6
No neoplasia	838(40)	46 (6); 4 - 7	15 (2); 1 - 3	52 (6); 5 - 8	1.2 (0.7 - 2)	0.4
IBD⁵	61 (3)	3 (5); 1 - 14	0 (0); 0 - 6	3 (5); 1 - 14	0.9 (0.3- 3)	0.01
Non neoplastic polyps⁶	296(14)	16 (5); 3 - 9	4 (2); 0.4 - 4	18 (6); 4 - 9	1.1 (0.6 - 2)	0.2
Hemorrhoids	288(60)	14 (5); 3 - 8	6 (2); 1 - 4	16 (6); 3 - 9	1.0 (0.5 - 2)	0.02
Angiodysplasia	11 (0.5)	2 (18); 2 - 52	0 (0); 0 – 28	2 (18); 2 - 52	4 (1 -19)	3
Diverticular disease	182(38)	11 (6); 3 - 11	5 (3); 1 - 6	13 (7); 4 - 12	1.3 (0.7 - 3)	0.8
Normal colon/rectum	450(21)	22 (5); 3 - 7	3 (1); 0 - 2	24 (5); 3 - 8	1	1

¹Calculation of Odds Ratios (OR) or Chi-square (X²) values against normal colon/rectum; *P-values <0.05, **P-values <0.001; ²Advanced adenoma including Stage 0 cancers; ³Excluding HGD; ⁴no HGD or TVA; ⁵Inflammatory bowel disease ⁶Hyperplastic, unspecified and other polyps
HGD high-grade dysplasia, TVA tubulovillous adenoma, TA tubular adenoma, IBD inflammatory bowel disease

Back to article page